Altriva is a USA-based pharmaceutical company dedicated to developing innovative therapies that improve lives. With FDA-approved facilities and a presence in over 30 countries, we deliver medicine you can trust.
Founded in Washington, D.C., Altriva Pharmaceuticals Inc. has grown into a trusted name in global health care. We specialize in the research, development, and distribution of high-quality pharmaceutical products across major therapeutic areas.
Our mission is to make life-saving and life-enhancing medicines accessible to patients worldwide. Every decision we make is guided by science, integrity, and a deep commitment to the communities we serve.
Learn Our StoryWe focus on four key therapeutic areas where we can make the greatest impact on patient health.
Advanced cardiovascular treatments including antihypertensives, lipid regulators, and heart failure therapies that save millions of lives annually.
Innovative oncology pipelines targeting breast, lung, colorectal, and rare cancers with cutting-edge precision medicine approaches.
Neurological therapies addressing migraine, epilepsy, Parkinson's, Alzheimer's, and other central nervous system disorders.
Antibiotics, antivirals, and vaccines combating emerging infectious threats and antimicrobial resistance globally.
Our state-of-the-art R&D facilities drive breakthrough discoveries that transform patient care.
With an annual R&D investment exceeding $200 million, Altriva is at the forefront of pharmaceutical innovation. Our research spans early-stage discovery through late-stage clinical development.
"Altriva's commitment to quality and compliance sets them apart. They've been a reliable partner in our supply chain for over a decade."
Chief Medical Officer, GlobalHealth Systems
"The level of innovation coming out of Altriva's research labs is remarkable. Their oncology pipeline shows real promise for difficult-to-treat cancers."
Director of Clinical Research, MedStar Institute
"Working with Altriva has been seamless. Their regulatory expertise and transparent communication make them an exemplary pharmaceutical partner."
VP Supply Chain, Pacific Medical Distributors
Altriva announced FDA approval of AP-2024, a next-generation anticoagulant for the prevention of stroke in patients with atrial fibrillation.
Positive topline results from the Phase III ONCO-301 trial demonstrate significant improvement in progression-free survival for lung cancer patients.
New regulatory approvals in Singapore, Malaysia, and Thailand extend Altriva's reach to over 30 countries worldwide.